A team of researchers at VCU Massey Comprehensive Cancer Center has identified a new pathway through which mutations in the tumor suppressor p53 gene—found very frequently in human tumors—hijack DNA ...
Memorial Sloan Kettering Cancer Center investigators and collaborators have tested rezatapopt, an oral p53 reactivator ...
The results of research headed by a team in the lab of Michael Sigal, MD, at the Max Delbrück Center and Charité—Universitätsmedizin Berlin, have shed new light on the role of the p53 tumor suppressor ...
Researchers in the lab of Michael Sigal at the Max Delbrück Center and Charité – Universitätsmedizin Berlin have elucidated the role of the p53 gene in ulcerative colitis. The study, published in ...
Investigation of the association of CTRB2 exon 6 deletion with time to progression and overall survival in pancreatic ductal adenocarcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO ...
Design of a phase 1 trial of Listeria monocytogenes 11-T856-1313 tetanus toxoid (Lm-LLO-TT) for pancreatic ductal adenocarcinoma (PDAC). This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Cancer begins when mutations in specific genes override the body’s built-in controls on cell division, allowing rogue cells ...
Schematic illustrating the effects of p53C and M237I in driving the conversion of p63C and p73C droplets into amyloid aggregates at physiologically relevant temperatures. Heparin prevents the ...
After more than a decade of research, scientists have discovered the natural mechanism behind a novel form of cell death ...